In July 2017, Graphite backed the management buy-out of Random42, a leading global 3D and Virtual Reality animation and digital media services provider to the healthcare and pharmaceutical industries.

Random42 produces complex, scientific animations to assist pharmaceutical and biotech companies in their interaction with and communication to a wide range of stakeholders. Animations, which are typically in a 3D or Virtual Reality format, are used for educational and promotional purposes throughout the lifecycle of healthcare products, from the pre-clinical stage, through to clinical trials, and as part of product launches and refreshes.

The company employs a combination of highly skilled graphic designers, software developers and scientists, enabling the business to generate high-quality, scientific animations, which demonstrate disease mechanisms and the ways in which molecular medical and pharmaceutical products interact with the human body. The company works directly with the majority of the top 25 pharmaceutical companies worldwide, including AstraZeneca, GSK, Merck, Novartis, Roche and Sanofi and with relationships across Europe, the US and Asia.

Graphite plans to support Random42 in its continued professionalisation and international expansion. With scalable account management and an active marketing strategy, there is significant scope for deeper customer and market penetration. We also believe there are exciting opportunities to diversify into adjacent markets, capitalising on the company’s historical success of combining scientific knowledge with outstanding media content production.